Skip to main content
. 2018 Oct 1;20(Suppl 4):iv1–iv86. doi: 10.1093/neuonc/noy131

Table 20.

One-, Two-, Five-, and Ten-Year Relative Survival Ratesa,b with 95% Confidence Intervals for Selected Malignant Brain and Other Central Nervous System Tumors Overall and by NCI Age Group, SEER 18 Registries, 2000-2015c

Histology Age Group (years) 1-Year 2-Year 5-Year 10-Year
N d % 95% CI % 95% CI % 95% CI % 95% CI
Pilocytic astrocytoma Childrene (0-14) 2,507 98.7 98.2-99.1 98.3 97.6-98.7 96.9 96.0-97.6 95.8 94.7-96.7
AYAf (15-39) 1,257 97.5 96.4-98.3 95.9 94.6-97.0 93.2 91.4-94.6 90.2 87.8-92.1
Adults (40+) 417 93.9 90.9-96.0 87.0 83.0-90.1 79.7 74.6-83.9 76.3 69.6-81.7
All Ages 4,181 97.9 97.4-98.3 96.4 95.8-97.0 94.1 93.2-94.8 92.2 91.0-93.2
Diffuse astrocytoma Childrend (0-14) 740 92.2 90.0-94.0 86.9 84.2-89.2 82.8 79.7-85.5 81.1 77.7-84.0
AYAe (15-39) 2,088 94.5 93.4-95.4 88.2 86.7-89.6 72.2 70.0-74.3 53.3 50.5-56.1
Adults (40+) 3,665 60.3 58.6-61.9 45.8 44.1-47.5 31.2 29.5-32.9 22.0 20.3-23.8
All Ages 6,493 74.9 73.8-76.0 64.2 62.9-65.4 50.4 49.0-51.7 39.3 37.8-40.8
Anaplastic astrocytoma Childrend (0-14) 248 62.7 56.3-68.5 33.5 27.4-39.6 21.9 16.6-27.7 16.1 11.1-21.9
AYAe (15-39) 1,266 90.5 88.7-92.0 76.5 73.9-78.9 55.7 52.4-58.8 40.3 36.6-44.0
Adults (40+) 3,022 55.0 53.1-56.8 35.2 33.4-37.0 19.8 18.2-21.5 13.1 11.5-14.8
All Ages 4,536 65.3 63.9-66.8 46.6 45.1-48.2 30.0 28.4-31.5 20.9 19.3-22.6
Glioblastoma Childrend (0-14) 348 52.9 47.4-58.0 28.8 23.9-33.9 19.6 15.3-24.4 14.8 10.6-19.7
AYAe (15-39) 1,998 74.3 72.2-76.2 48.0 45.6-50.2 22.7 20.7-24.8 13.7 11.8-15.7
Adults (40+) 34,270 38.1 37.5-38.6 15.5 15.1-15.9 4.3 4.1-4.6 1.9 1.7-2.2
All Ages 36,616 40.2 39.7-40.7 17.4 17.0-17.8 5.6 5.3-5.8 2.8 2.6-3.1
Oligodendroglioma Childrend (0-14) 129 95.2 89.6-97.8 94.4 88.5-97.3 89.7 82.4-94.0 88.6 80.9-93.3
AYAe (15-39) 1,388 99.1 98.3-99.5 97.3 96.2-98.1 89.9 87.9-91.6 74.4 71.3-77.3
Adults (40+) 1,925 91.4 90.0-92.7 85.4 83.6-87.1 75.0 72.7-77.2 58.5 55.4-61.5
All Ages 3,442 94.7 93.8-95.4 90.6 89.5-91.6 81.6 80.1-83.1 66.3 64.1-68.4
Anaplastic oligodendroglioma Childrend (0-14) -- -- -- -- -- -- -- -- --
AYAe (15-39) 401 93.6 90.7-95.7 85.2 81.1-88.5 72.3 67.1-76.8 56.4 49.9-62.5
Adults (40+) 1,086 80.9 78.3-83.2 67.7 64.6-70.6 52.3 48.9-55.7 39.4 35.5-43.2
All Ages 1,499 84.4 82.4-86.2 72.4 69.9-74.8 57.6 54.7-60.4 44.1 40.7-47.4
Ependymal tumors Childrend (0-14) 733 95.1 93.1-96.4 87.7 84.9-90.0 74.9 71.2-78.3 65.8 61.3-69.8
AYAe (15-39) 890 96.9 95.5-97.9 94.6 92.7-95.9 90.6 88.1-92.5 86.8 83.5-89.4
Adults (40+) 1,532 92.6 91.0-93.9 89.6 87.7-91.2 86.2 83.8-88.2 81.9 78.6-84.8
All Ages 3,155 94.4 93.5-95.2 90.5 89.3-91.6 84.8 83.2-86.2 79.5 77.4-81.4
Oligoastrocytic tumors Childrend (0-14) 76 94.7 86.2-98.0 88.9 78.9-94.3 82.5 71.0-89.8 80.6 68.6-88.4
AYAe (15-39) 968 97.2 95.9-98.1 91.7 89.6-93.3 75.6 72.4-78.5 56.2 51.9-60.3
Adults (40+) 1,191 81.4 79.0-83.6 68.5 65.6-71.2 52.6 49.4-55.7 39.7 35.9-43.4
All Ages 2,235 88.7 87.3-90.0 79.2 77.4-80.9 63.7 61.4-65.8 48.3 45.5-51.0
Glioma malignant, NOS Childrend (0-14) 1,756 77.1 75.0-79.1 66.0 63.6-68.2 63.4 61.0-65.7 61.8 59.2-64.2
AYAe (15-39) 1,029 89.7 87.6-91.5 82.8 80.2-85.1 72.8 69.6-75.8 62.5 58.3-66.4
Adults (40+) 2,420 49.0 46.9-51.0 38.3 36.2-40.4 30.3 28.2-32.5 24.9 22.6-27.3
All Ages 5,205 66.6 65.3-67.9 56.6 55.1-58.0 50.1 48.6-51.6 45.2 43.6-46.9
Neuronal and mixed neuronal-glial tumors Childrend (0-14) -- -- -- -- -- -- -- -- --
AYAe (15-39) 150 95.2 90.1-97.7 89.3 82.7-93.5 78.5 70.0-84.8 70.5 60.1-78.7
Adults (40+) 416 90.1 86.5-92.8 84.0 79.6-87.5 76.0 70.4-80.7 59.0 50.9-66.3
All Ages 611 91.6 88.9-93.7 85.8 82.5-88.6 77.6 73.3-81.3 64.8 58.9-70.2
Embryonal tumors Childrend (0-14) 2,083 80.6 78.8-82.3 71.0 68.9-73.0 62.6 60.3-64.8 56.4 53.9-58.9
AYAe (15-39) 793 88.2 85.7-90.3 80.4 77.3-83.1 65.8 62.0-69.4 58.9 54.7-62.9
Adults (40+) 248 72.9 66.7-78.1 58.5 51.8-64.6 45.7 38.7-52.4 31.5 24.1-39.2
All Ages 3,124 81.9 80.5-83.2 72.4 70.7-74.0 62.1 60.2-63.9 55.1 53.0-57.2
Medulloblastoma Childrend (0-14) 1,194 88.5 86.5-90.2 81.6 79.1-83.7 72.8 69.9-75.4 65.4 62.0-68.5
AYAe (15-39) 576 91.5 88.8-93.6 86.9 83.7-89.6 75.1 70.8-78.8 67.6 62.6-72.1
Adults (40+) 124 86.4 78.7-91.4 79.6 70.9-85.9 69.0 58.8-77.1 47.5 35.0-59.1
All Ages 1,894 89.3 87.7-90.6 83.0 81.2-84.7 73.2 71.0-75.3 64.9 62.2-67.5
PNET Childrend (0-14) 399 77.9 73.4-81.7 62.1 57.0-66.8 54.7 49.5-59.7 49.0 43.6-54.3
AYAe (15-39) 148 80.8 73.3-86.3 61.8 53.2-69.3 39.4 30.8-47.8 34.4 25.9-43.0
Adults (40+) 96 55.8 45.0-65.3 35.6 25.8-45.6 20.6 12.5-30.2 -- --
All Ages 643 75.3 71.7-78.5 58.1 54.1-62.0 46.4 42.2-50.4 40.8 36.6-45.0
ATRT Childrend (0-14) 283 51.6 45.5-57.4 38.7 32.6-44.6 32.2 26.2-38.3 28.7 22.6-35.1
AYAe (15-39) -- -- -- -- -- -- -- -- --
Adults (40+) -- -- -- -- -- -- -- -- --
All Ages 293 52.6 46.6-58.3 39.8 33.9-45.7 32.0 26.1-38.0 28.6 22.5-34.9
Meningioma Childrend (0-14) -- -- -- -- -- -- -- -- --
AYAe (15-39) 98 97.0 90.5-99.1 97.0 90.5-99.1 89.0 79.7-94.1 83.2 72.0-90.2
Adults (40+) 1,119 80.8 78.2-83.2 72.9 69.9-75.7 61.5 57.9-64.9 53.5 49.2-57.5
All Ages 1,229 82.1 79.6-84.3 74.9 72.1-77.5 63.8 60.5-67.0 56.1 52.1-59.9
Lymphoma Childrend (0-14) -- -- -- -- -- -- -- -- --
AYAe (15-39) 573 59.1 54.8-63.1 54.2 49.8-58.3 48.9 44.5-53.2 45.2 40.5-49.7
Adults (40+) 4,591 52.6 51.1-54.1 43.8 42.2-45.3 32.2 30.6-33.8 23.5 21.7-25.3
All Ages 5,203 53.6 52.2-55.0 45.2 43.8-46.6 34.5 33.0-36.0 26.6 24.9-28.3
TOTAL Children d (0-14) 9,699 86.2 85.4-86.9 78.7 77.9-79.6 73.3 72.4-74.3 69.9 68.8-70.9
AYA e (15-39) 14,189 89.7 89.2-90.2 81.3 80.6-81.9 68.3 67.5-69.2 57.2 56.1-58.2
Adults (40+) 59,272 48.4 48.0-48.8 31.1 30.7-31.5 20.3 19.9-20.6 15.4 15.0-15.8
All Ages 83,160 59.9 59.6-60.3 45.4 45.0-45.8 35.0 34.6-35.3 29.3 28.9-29.7

aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.

bRates are an estimate of the percentage of patients alive at one, two, five, and ten years, respectively. Rates were not presented for categories with 50 or fewer cases and were suppressed for rates where fewer than 16 cases were surviving within a category.

cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2017 Sub (2000-2015) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2018, based on the November 2017 submission.

dTotal number of case that occurred within the SEER registries between 2000 and 2015.

eChildren as defined by the National Cancer Institute, see: http://www.cancer.gov/researchandfunding/snapshots/pediatric.

fAdolescents and Young Adults (AYA), as defined by the National Cancer Institute, see: http://www.cancer.gov/researchandfunding/snapshots/adolescent-young-adult.

gTotal includes histologies not listed in this table.

-- Counts and rates are not presented for categories with 50 or fewer cases and were suppressed for rates where fewer than 16 cases were surviving within a category. The suppressed cases are included in the counts and rates for totals.

Abbreviation: CBTRUS, Central Brain Tumor Registry of the United States; SEER, Survival, Epidemiology, and End Results; CI, confidence interval; NOS, not otherwise specified